Abstract:
Aspects of a method and system for a programmable interference suppression module may include receiving a communication signal comprising one or more desired signal, and one or more undesired signals. The communication signal may be utilized to generate estimated channel state information. The estimated channel state information may be formatted for use in interference suppression. A reduced interference signal may be generated from a delayed version of said communications signal and the estimated channel state information, wherein the one or more undesired signals may be attenuated. The reduced interference signal may be formatted for post-processing. The desired signals may comprise WCDMA and/or HSDPA signals, and the undesired signals may be inter-cell and/or intra-cell interference. Further processing may comprise HSDPA processing and/or RAKE finger processing. The communication signal may be a Universal Mobile Telecommunication System (UMTS) compliant signal.
Abstract:
A universal smart interface and peripheral management system for portable devices such as mobile phones. The smart system includes a connector interface that connects peripherals to a phone and/or personal digital assistant (PDA), through the smart system. The smart system includes a cradle for receiving a cell phone and interfacing the phone to external systems such as peripherals, networks and other systems through a USB hub and other suitable connector interfaces. The peripheral devices to which the smart system can interface include, but are not limited to, large displays (e.g., television), external monitors, input devices such as mice and keyboards, external storage devices, and networks (wired and/or wireless). The smart system also facilitates connectivity to large display systems such as TVs, computer displays and monitors.
Abstract:
The present invention is directed to a compound having the formula wherein R1, R2, G, and Q are defined herein. The compounds of the present invention are useful as inhibitors of protein kinases such as MAP kinases, in particular p38 kinases. The present invention is also directed to compositions comprising a compound according to the above formula. The compounds and compositions described herein are useful for treating and preventing an inflammatory condition or disease. The present invention is also directed to a method of treating or preventing a protein kinase-mediated condition.
Abstract:
A multiprocessor system (100) for sharing memory has a memory (102), and two or more processors (104). The processors are programmed to establish (202) memory buffer pools between the processors, and for each memory buffer pool, establish (204) an array of buffer pointers that point to corresponding memory buffers. The processors are further programmed to, for each array of buffer pointers, establish (206) a consumption pointer for the processor owning the memory buffer pool, and a release pointer for another processor sharing said memory buffer pool, each pointer initially pointing to a predetermined location of the array, and adjust (208-236) the consumption and release pointers according to buffers consumed and released.
Abstract:
A universal smart interface and peripheral management system for portable devices such as mobile phones. The smart system includes a connector interface that connects peripherals to a phone and/or personal digital assistant (PDA), through the smart system. The smart system includes a cradle for receiving a cell phone and interfacing the phone to external systems such as peripherals, networks and other systems through a USB hub and other suitable connector interfaces. The peripheral devices to which the smart system can interface include, but are not limited to, large displays (e.g., television), external monitors, input devices such as mice and keyboards, external storage devices, and networks (wired and/or wireless). The smart system also facilitates connectivity to large display systems such as TVs, computer displays and monitors.
Abstract:
Methods, compositions and articles of manufacture involving soluble conjugated polymers are provided. The conjugated polymers have a sufficient density of polar substituents to render them soluble in a polar medium, for example water and/or methanol. The conjugated polymer may desirably comprise monomers which alter its conductivity properties. In some embodiments, the inventors have provided cationic conjugated polymers (CCPs) comprising both solubilizing groups and conductive groups, resulting in conductive conjugated polymers soluble in polar media. The different solubility properties of these polymers allow their deposition in solution in multilayer formats with other conjugated polymers. Also provided are articles of manufacture comprising multiple layers of conjugated polymers having differing solubility characteristics. Embodiments of the invention are described further herein.
Abstract:
The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.
Abstract:
Methods, compositions and articles of manufacture involving cationic conjugated conformationally flexible polymers are provided. A method for the synthesis of cationic water-soluble polymers with linkages along the polymer main chain structure which disrupt the ability of the polymers to form extended-rod structures is provided. Such polymers may serve in the fabrication of novel optoelectronic devices and in the development of highly efficient biosensors. The invention further relates to the application of these polymers in assay methods.
Abstract:
The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3—R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, non-small cell lung and colon.